• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
OPT
Click for more information
2.31% 66.5¢

OPTHEA LIMITED - News & Media

Market Cap $430.8M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No News & Media currently available.

(20min delay)
Last
66.5¢ 		Change
0.015(2.31%) 		Mkt cap ! $430.8M
Open High Low Value Volume
66.0¢ 67.0¢ 66.0¢ $33.99K 51.29K

Buyers (Bids)

No. Vol. Price($)
4 3394 66.0¢
 

Sellers (Offers)

Price($) Vol. No.
66.5¢ 5842 5
View Market Depth
Last trade - 10.40am 15/05/2024 (20 minute delay) ?
Last
65.8¢ 		  Change
0.015 ( 0.72 %)
Open High Low Volume
66.0¢ 66.5¢ 65.8¢ 14457
Last updated 10.58am 15/05/2024 ?
OPT (ASX) Chart

Top Stories

Calmer Co clocks $150K in sales of its kava-based health drinks at Coles

When microcap consumer health brand stock Calmer Co stacked its products on the shelves at Coles, it knew it was onto a good thing.
Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug bisantrene
D3E joins ASX as it hunts natural gas and helium in South Africa D3E Energy will begin trading on the Australian Stock Exchange at 11 am today, having listed late last week, with shares priced at 20 cents.
BHP fails to secure second takeover offer to Anglo American BHP Group Ltd has failed in a second bid to takeover Anglo American Plc through a scheme of arrangement offer.
Raiden inches closer to Andover South drilling as heritage report clears land Raiden Resources has confirmed that its final heritage report for the Andover South lithium project has cleared the way for drilling.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.